ARTICLE TEXT The United States Food and Drug Modernization Act (FDAMA) took effect in 1998 with high expectations from the pharmacoeconomics community. Section 114 of the Act stipulated the conditions under which drug companies could promote health economic information to their managed care customers, and seemingly would make it easier for pharmacoeconomic modelers and outcomes researchers to c...

SCOTT BULL, PHARM.D., is a Pharmacy Research Analyst, Kaiser Permanente Division of Research, Oakland, CA At the time of the study, he was Pharmacoeconomics/Outcomcs Research Fellow, Novartis Pharmaceuticals/Kaiser Permanente. OMAR SHOHEIBER, PHARMD., is Vice PresidcntPmduct Development, Tricore Technologies, North Brunswick, NJ At the time of the study, he was Associate Director, Outcomes Rese...

5-Fluorouracil (5-FU) is cell-cycle specific for its cytotoxicity and has a pharmacokinetic profile characterized by a short, single-dose half-life of 10 to 20 minutes in plasma. Efforts to maximize its clinical efficacy have been directed at overcoming this short half-life. Strategies have included prolonging intracellular exposure by biochemical modulation or administration by infusional sche...

Spiraling health care costs have prompted great interest in evaluating the pharmacoeconomics of all medical treatments [1]. As a result of careful analyses, it has been suggested that the most cost-effective approach to therapy may not necessarily be the least expensive but rather the one that provides the best clinical outcome. Length of hospitalization and incidence of adverse effects or dise...

Supplement to Annals of Long-Term Care and Clinical Geriatrics A Freedom Magazines Publication EDUCATIONAL OBJECTIVES Upon completion of this activity, participants should be able to: • Discuss the impact of declining cognition, function, and behavior of patients with Alzheimer’s disease on managed care pharmacoeconomics. • Utilize disease stage–appropriate evaluation methods to assess disease ...